Full Text:   <2572>

CLC number: R571

On-line Access: 

Received: 2002-08-29

Revision Accepted: 2002-12-20

Crosschecked: 0000-00-00

Cited: 0

Clicked: 5241

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE A 2003 Vol.4 No.5 P.602-606


Quality of life and cost-effectiveness of combined therapy for reflux esophagitis

Author(s):  SI Jian-min, WANG Liang-jing, CHEN Shu-jie, ZHAO Lan, DAI Ning

Affiliation(s):  Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China

Corresponding email(s):   sijm@163.net

Key Words:  Reflux esophagitis(RE), Quality of life, Cost-effectiveness

Share this article to: More

SI Jian-min, WANG Liang-jing, CHEN Shu-jie, ZHAO Lan, DAI Ning. Quality of life and cost-effectiveness of combined therapy for reflux esophagitis[J]. Journal of Zhejiang University Science A, 2003, 4(5): 602-606.

@article{title="Quality of life and cost-effectiveness of combined therapy for reflux esophagitis",
author="SI Jian-min, WANG Liang-jing, CHEN Shu-jie, ZHAO Lan, DAI Ning",
journal="Journal of Zhejiang University Science A",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Quality of life and cost-effectiveness of combined therapy for reflux esophagitis
%A SI Jian-min
%A WANG Liang-jing
%A CHEN Shu-jie
%A DAI Ning
%J Journal of Zhejiang University SCIENCE A
%V 4
%N 5
%P 602-606
%@ 1869-1951
%D 2003
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2003.0602

T1 - Quality of life and cost-effectiveness of combined therapy for reflux esophagitis
A1 - SI Jian-min
A1 - WANG Liang-jing
A1 - CHEN Shu-jie
A1 - ZHAO Lan
A1 - DAI Ning
J0 - Journal of Zhejiang University Science A
VL - 4
IS - 5
SP - 602
EP - 606
%@ 1869-1951
Y1 - 2003
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2003.0602

Objective: To evaluate clinical, quality of life (QoL) and medical cost outcomes in patients with symptomatic reflux esophagitis (RE) receiving different "triple combination therapy". Methods: A multicenter medical effectiveness trial conducted in 10 hospitals of 5 regions in Zhejiang Province. 248 patient-volunteers were assigned to 8 weeks of "triple combination therapy" with Lansoprazole plus Cisapride and Sucralfate or Ranitidine plus Cisapride and Sucralfate. Main outcomes assessment included symptoms scale scores, RE severity, QoL at baseline and 8 weeks. Medical cost data were collected with cost analysis questionnaire. Results: (1) More Lansoprazole group patients noted RE symptoms resolution than Ranitidine group (92.3% vs 78.4%, P<0.01). There was no striking difference between two groups in RE healing rate (90.8% vs 82.9%, P>0.05). (2) RE significantly impaired QoL of patients (P<0.001).Compared with Ranitidine group, QoL in Lansoprazole group had significant improvement (rate of "good" QoL 64.5% vs 45.6%, P<0.01). (3)There was close correlation between symptomic effectiveness and QoL rating scale in both the Lansoprazole and Ranitidine group (P<0.01, r=0.235 and 0.353 respectively). There were no statistical difference of medical cost between the two groups (P>0.05). Conclusion: RE significantly impaired QoL of patients. "Triple combination therapies" can significantly improve RE symptoms and QoL. Lansoprazole combination therapy was more cost-effective than Ranitidine combination group.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1]Bloom, B.S.,Hillman, A.L. and Lammont, B., 1995. Omeprazole or ranitidine plus metoclopramide for patients with severe esophagitis: a cost-effetiveness analysis. Pharmacoeconomic, 8:343-349.

[2]Devault, K.R. and Castell, D.O., 1995. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch. Intern. Med., 155:2165-2173.

[3]Hawden, C.W.,Castell, D.O. and Cohen, S., 1995. The rational for continuous maintenance treatment of reflux esophagitis. Arch. Intern. Med., 155:1465-1471.

[4]Mathias, S.D., Castell, D.O. and Elkin, E.P., 1996. Health-related quality of life of patients with acute erosive reflux esophagitis. Dis Sci., 41:2123-2123.

[5]McDougall, N.I., Johnston, B.T. and Kee, F., 1996. Natural history of reflux oesophagitis: a 10-year followup of its effect on patients symptomatology and quality of life. Gut., 38:481-486.

[6]Mckenna, C.J., Mills, J.G. and Gooduin, C., 1995. Combination of ranitidine and cisapride in the treatment of reflux oeseophagitis. Eur. J. Gastroenterol Hepatol, 7: 817-822.

[7]Pan, G.Z., Xu, G.M. and Guo, H.P., 1999. An epidemiologic study on gastroesophageal reflux symptoms in Beijing and Shanghai. Chinese Journal of Digestion, 19:223-226(in Chinese with English abstract).

[8]Vic, Velanovich, 2000.Quality of life and severity of symptoms in gastro-oesophageal reflux disease: a clinical review. Eur. J. Surg., 166:516-525.

[9]Vigneri, S., Termini, R. and Leandro, G., 1995. A comparison of five maintenance therapies for reflux esophagitis. N. Eng. J. Med., 333:1106-1110.

[10]Yang, L., Li, C.Y. and Wu, J.C., 1997. Study of effectiveness of ranitidine plus cisapride compared ranitidine for GERD. Chinese Journal of Endoscopy, 3:9-10(in Chinese with English abstract).

[11]Zagari, M.,Villa, K.F. and Freston, J.W., 1995. Proton pump inhibitors versus H2-receptor anatagonists fot the treatment of erosive gastroesophageal reflux disease: A cost comparative study. Am. J. Man. Care., 1:247-255.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE